



Drug Therapy Protocols: Lidocaine 1% (Lignocaine 1%)

Policy code	DTP_LID_0722
Date	July, 2022
Purpose	To ensure a consistent procedural approach to lidocaine 1% (lignocaine 1%) administration.
Scope	Applies to all Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless specifically mentioned.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	July, 2024
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2022.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au

Lidocaine 1% (lignocaine 1%)

July, 2022

Drug class

Local anaesthetic^[1,2]

Pharmacology

Lidocaine (lignocaine 1%) stabilises the neuronal membrane and prevents the transmission of nerve impulses, thereby effecting a local anaesthetic action.^[1,2]

Metabolism

80% metabolised by the liver and the remainder is excreted by the kidneys.^[1]

Indications

- **Pain associated with IO drug and fluid administration following EZ-IO® needle insertion**
- **Local anaesthesia** (for the purpose of radial artery line replacement, skin closure – suturing, fishhook removal AND/OR thoracostomy)
- **To reconstitute ceftriaxone for the purpose of IM injection**

Contraindications

- Allergy AND/OR Adverse Drug Reaction

Precautions

- Inadvertant intravascular injection
- Severe kidney or liver disease

Side effects

- Convulsions
- Hypotension
- Nausea
- Tinnitus

Presentation

- Ampoule, 50 mg/5 mL *lidocaine (lignocaine 1%)*

Onset (SUBCUT)	Duration (SUBCUT)	Half-life
1–10 minutes	Up to 1 hour	Not applicable

Schedule

- S₄ (Restricted drugs).

Routes of administration

Intraosseous injection (IO)



Subcutaneous injection (SUBCUT)



Intramuscular injection (IM)



Special notes

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the *QAS Clinical Consultation and Advice Line*.
- Local anaesthesia injections should always be administered slowly with frequent aspirations to avoid inadvertent intravascular injection.
- All cannulae and IV lines must be flushed thoroughly with sodium chloride 0.9% following each medication administration.

Adult dosages^[1-4]

Pain associated with IO drug and fluid administration following EZ-IO® needle insertion

	IO	60 mg. (Administer 40 mg over 2 minutes, allow lidocaine to dwell in IO space for 1 minute, administer a rapid 10 mL sodium chloride 0.9% flush and then administer and additional 20 mg of lidocaine over 1 minute). Total max dose 60 mg.
--	----	--

Local anaesthesia (for the purpose of radial artery line placement, regional anaesthesia (digital block), skin closure – suturing, fishhook removal AND/OR thoracostomy)

	SUBCUT	Up to 3 mg/kg (0.3 mL/kg) of lidocaine 1% (lignocaine 1%). Total maximum infiltration 200 mg (20 mL).
--	--------	--

To reconstitute ceftriaxone for the purpose of IM injection

	IM	As authorised on DTP: Ceftriaxone
--	----	--

Paediatric dosages^[1-4]

Pain associated with IO drug and fluid administration following EZ-IO® needle insertion

	IO	0.75 mg/kg. (Administer 0.5 mg/kg (max 40 mg) over 2 minutes, allow lidocaine to dwell in IO space for 1 minute, administer a rapid 5 mL sodium chloride 0.9% flush and then administer an additional half initial dose of lidocaine (max 20 mg) over 1 minute. Total max dose 60 mg.
--	----	---

Local anaesthesia (for the purpose of radial artery line placement, regional anaesthesia (digital block), skin closure – suturing, fishhook removal AND/OR thoracostomy)

	SUBCUT	Up to 3 mg/kg (0.3 mL/kg) of lidocaine 1% (lignocaine 1%). Total maximum infiltration 150 mg (15 mL).
--	--------	--

To reconstitute ceftriaxone for the purpose of IM injection

	IM	As authorised on DTP: Ceftriaxone
--	----	--